今月の研究者

浦上 慎司

浦上 慎司

1)簡単なキャリア(研究面・臨床面)
私は1994年に島根医科大学医学部医学科を卒業後、同大学泌尿器科学教室に入局すると同時に、同大学大学院医学研究科機能系専攻博士課程へ進学いたしました。医師として大学病院で臨床研修に励む傍ら、大学院では手始めに、臨床業務終了後に「泌尿器科癌の免疫組織学的研究」を細々と行なっておりました。当時、泌尿器科分野では、癌抑制遺伝子の一つであるvon Hippel-Lindau遺伝子(Vhl遺伝子)の変異について、腎癌での臨床上の意義が明らかになりつつある時期で、私は「泌尿器科癌の多段階発癌」に強く興味を惹かれていきました。大学院の2年目に、網膜芽細胞腫の原因遺伝子であるRb遺伝子「2ヒット・セオリー」で世界的に有名なFox Chase Cancer Center/NCI のKnudson教授の研究室から帰国されたばかりの樋野興夫先生(現順天堂大学分子病理病態学(病理・腫瘍学)教授)の御講演を拝聴したことがきっかけで、彼が当時主宰する癌研究会/癌研究所実験病理部へ国内留学をする機会を頂き、多くの分子生物学的手法を取得し、ヒト結節性硬化症の原因遺伝子の一つで、ラットの遺伝性腎癌の原因遺伝子でもあるTsc2の解析を2年間行いました。その結果をまとめた論文「Somatic mutation of the tuberous sclerosis (Tsc2) tumor suppressor gene in chemically induced rat renal carcinoma cell」で、1998年に島根医科大学より医学博士の学位を授与され、大学院を卒業いたしました。
 大学院卒業後は、母校である島根医科大学(現島根大学医学部)泌尿器科学教室で、井川幹夫教授(現島根大学付属病院長)のもと、助手・講師を拝命頂きました。大学では、大学院で学んだ知識と、臨床での経験を生かして、「去勢抵抗性前立腺癌の発生機序の解明とその治療法の開発」に熱心に取り組み、日本における去勢抵抗性前立腺癌に対するタキサン系抗がん剤の導入に微力ながら尽力させて頂きました。  
また、2004年から2006年までの2年間、カリフォルニア大学サンフランシスコ校泌尿器科へ留学し、大学院時代に培った分子生物学的手法を駆使して、泌尿器科臨床医のバイブルであるSmith’s General Urologyの筆者であるTanagho教授の御指導のもと再生医療の先駆け的研究でもある「acellular matrix graftを用いた脊髄損傷による神経因性膀胱の膀胱再生」についてラットを用いて研究し、同時に泌尿器科基礎研究分野のDahiya教授のもとで癌とエピジェネティクス異常の研究である「泌尿器科癌のWNT阻害蛋白遺伝子群のメチル化異常」にも従事しました。
帰国後は、大学での研究・教育を中心とした生活から、一般病院での臨床を中心とした生活へ転換しようと考えていた時期に、縁あって国内留学中に出入りさせて頂いていた癌研病院泌尿器科の福井巌先生(当時副病院長)に声をかけて頂き、2008年に(財)癌研有明病院泌尿器科医長に採用・赴任することになり、ひたすら多数の泌尿器科癌の手術と薬物療法の経験を積ませて頂くと同時に、臨床的研究(拡大手術と集学的治療の意義)にも没頭し、研鑽を積ませて頂きました。現在は、2014年より虎の門病院泌尿器科で岡根谷利一部長の下、医長を拝命し、幅広く泌尿器科手術を経験させて頂いております。

所属学会
日本泌尿器科学会会員(泌尿器科専門医、指導医)
日本がん治療認定機構(がん治療認定医)
日本ミニマム創泌尿器内視鏡外科学会会員(腹腔鏡下小切開手術施設基準医)
日本泌尿器内視鏡学会会員(泌尿器腹腔鏡技術認定医)
日本内視鏡外科学会会員(技術認定医)
日本癌治療学会会員
日本泌尿器腫瘍学会会員
日本内分泌学会会員(内分泌代謝科(泌尿器科)専門医認定申請中)

島根大学臨床教授

賞罰
西日本泌尿器科最優秀論文賞(重松賞)
第101回アメリカ泌尿器科学会 Annual Audio-Visual Award、Second Prize
IJU Best Reviewer of the year (2014)

2)研究分野
尿路上皮癌
 cN 尿路上皮がんにおける導入化学療法後救済手術の意義と適応
 浸潤性尿路上皮がんにおける術後補助化学療法の適応と適応
 転移性尿路上皮癌の転移巣切除の意義と適応
 膀胱上皮内癌に対するBCG膀胱内注入療法の治療成績におけるアミノレブリン酸を用いた光力学診断併用経尿道的膀胱腫瘍切除の有用性
 ロボット支援膀胱全摘時代における腹腔鏡下根治的膀胱全摘の位置づけと適応
腎癌
 透析患者に発生した腎腫瘍の組織型再分類とその臨床像の検討
 希少腎癌の臨床統計
 非転移性腎癌におけるリンパ節郭清の意義
 ロボット支援腎部分切除時代における鏡視下腎部分切除の位置づけと適応
 下大静脈腫瘍塞栓を伴う非転移性腎細胞癌に対する手術の予後因子解析からみた治療戦略
前立腺癌
 ロボット支援前立腺全摘時代における開放前立腺全摘除術の位置づけと適応
副腎腫瘍
 転移性副腎腫瘍に対する腹腔鏡下副腎摘除術の意義と適応
精巣腫瘍
 MD-CT導入後の精巣がんstage Ⅰに対するsurveillance policyの治療成績
リンチ症候群
 ユニバーサルスクリーニングによるリンチ症候群を背景と考えられる泌尿器癌(上部尿路上皮癌・膀胱癌・前立腺癌)の有病率の推定およびその臨床病理学的特徴の検討
良性疾患
 前立腺肥大症 
比較的軽度の前立腺肥大症に対する経尿道的前立腺レーザー核出術(HoLEP)の有用性
α1遮断薬の投与後に残存する蓄尿症状を有する前立腺肥大症患者に対するタダラフィルおよびソリフェナシン追加投与の無作為比較試験
 膀胱炎
  同種造血幹細胞移植後のウイルス性出血性膀胱炎に対する泌尿器科的外科治療の意義
 血尿
  ランニング後の運動性無症候性肉眼的血尿の原因の検討
  
3)今後の抱負、アピール
当科は高度先進医療を担う病院でありながら、良性悪性を問わず、幅広い疾患に対応できる診療体制を整えています。今後は、これまで培った経験と技術をもとに、臨床面では拡大手術と腹腔鏡下手術などの低侵襲手術を軸として、悪性疾患はもちろん、良性疾患も含めてオールラウンドに手術手技を習得し、研鑽を積むことで臨床的能力を磨き、研究面では日常診療で生じる臨床医ならではの“クリニカル・クエスチョン”を学術的な視点で検証し、英語論文として報告することを心掛けてまいります。

4)その他(研究活動一般への業績論文)

発表・論文

学術論文

外国語文

1. Urakami S, Ogawa K, Oka S, Hagiwara K, Nagamoto S, Anjiki H, Hayashida M, Yano A, Sakaguchi K, Kurosawa K, Okaneya T. Effect of tadalafil add-on therapy in patients with persistant storage symptoms refractory to α1 -adrenoceptor antagonist monotherapy for benign prostatic hyperplasia: A randomized pilot trial comparing tadalafil and solifenacin.
Low Urin Tract Symptoms. 2018 Sep 24.

2. Oka S, Inoshita N, Miura Y, Oki R, Miyama Y, Nagamoto S, Ogawa K, Sakaguchi K, Kondoh C, Kurosawa K, Urakami S, Takano T, Okaneya T. The loss of BAP1 protein expression predicts poor prognosis in patients with nonmetastatic clear cell renal cell carcinoma with inferior vena cava tumor thrombosis.
Urol Oncol. 2018 Aug;36(8):365.e9-365.e14.

3. Yuasa T, Urakami S, Yonese J. Recent advances in medical therapy for metastatic urothelial cancer.
Int J Clin Oncol. 2018 Aug;23(4):599-607.

4. Urakami S, Inoshita N, Oka S, Miyama Y, Nomura S, Arai M, Sakaguchi K, Kurosawa K, Okaneya T. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
Int J Urol. 2018 Feb;25(2):151-156.

5. Nakagawa T, Taguchi S, Kanatani A, Kawai T, Ikeda M, Urakami S, Matsumoto A, Komemushi Y, Miyakawa J, Yamada D, Suzuki M, Enomoto Y, Nishimatsu H, Kondo Y, Nagase Y, Hirano Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Oncologic Outcome of Metastasectomy for Urothelial Carcinoma: Who Is the Best Candidate?
Ann Surg Oncol. 2017 Sep;24(9):2794-2800.

6. Ikeda M, Matsumoto K, Sakaguchi K, Ishii D, Tabata KI, Kurosawa K, Urakami S, Okaneya T, Iwamura M. Effect of Lymphadenectomy During Radical Nephroureterectomy in Locally Advanced Upper Tract Urothelial Carcinoma.
Clin Genitourin Cancer. 2017 Oct;15(5):556-562.

7. Miura Y, Inoshita N, Ikeda M, Miyama Y, Oki R, Oka S, Kondoh C, Ozaki Y, Tanabe Y, Kurosawa K, Urakami S, Kohno T, Okaneya T, Takano T. Loss of BAP1 protein expression in the first metastatic site predicts prognosis in patients with clear cell renal cell carcinoma.
Urol Oncol. 2017 Jun;35(6):386-391.

8. Kurosawa K, Urakami S, Ishiwata K, Miyagawa J, Sakaguchi K, Fujioka M, Murata H, Inoshita N, Taniguchi S, Okaneya T. Significance of Urological Surgical Treatment for Viral Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation.
Hinyokika Kiyo. 2016 Nov;62(11):563-567.

9

. Tabata M, Urakami S, Takahashi S, Sakaguchi K, Ikeda M, Kurosawa K, Okaneya T, Homma Y. ACHIEVED REMARKABLE IMPROVEMENTS IN PERFORMANCE STATUS WHEN TREATED WITH COMBINATION CHEMOTHERAPY WITH GEMCITABINE AND DOCETAXEL.
Nihon Hinyokika Gakkai Zasshi. 2016;107(4):256-260.

10. Kurosawa K, Urakami S, Ikeda M, Tabata M, Murata H, Okaneya T. Clinicopathological Study and Treatment Outcome of Retroperitoneal Soft Tissue Sarcoma.
Hinyokika Kiyo. 2015 Nov;61(11):419-26.

11. Urakami S, Okaneya T. Editorial Comment to Effect of preoperative chemotherapy on survival of patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes.
Int J Urol. 2016 Feb;23(2):158-9.

12. Tabata M, Ikeda M, Urakami S, Takahashi S, Sakaguchi K, Kurosawa K, Okaneya T. Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy.
Jpn J Clin Oncol. 2015 Oct;45(10):963-7.

13. Tanaka H, Yoshida S, Komai Y, Sakai Y, Urakami S, Yuasa T, Yamamoto S, Masuda H, Koizumi M, Kohno A, Fukui I, Yonese J, Fujii Y, Kihara K. Clinical Value of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Upper Tract Urothelial Carcinoma: Impact on Detection of Metastases and Patient Management.
Urol Int. 2016;96(1):65-72.

14. Urakami S, Yuasa T, Yamamoto S, Sakura M, Tanaka H, Hayashi T, Uehara S, Inoue Y, Fujii Y, Masuda H, Fukui I, Yonese J. Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery.
Int J Clin Oncol. 2015 Dec;20(6):1171-8.

15. Yuasa T, Inoshita N, Tanaka H, Urakami S, Yamamoto S, Fujii Y, Masuda H, Fukui I, Ishikawa Y, Yonese J. Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era.
Int J Clin Oncol. 2015 Dec;20(6):1198-202.

16. Yuasa T, Inoshita N, Saiura A, Yamamoto S, Urakami S, Masuda H, Fujii Y, Fukui I, Ishikawa Y, Yonese J. Clinical outcome of patients with pancreatic metastases from renal cell cancer.
BMC Cancer. 2015 Feb 12;15:46.

17. Yamamoto S, Masuda H, Urakami S, Fujii Y, Sakamoto K, Kozuka T, Oguchi M, Fukui I, Yonese J. Patient-perceived satisfaction after definitive treatment for men with high-risk prostate cancer: radical prostatectomy vs. intensity-modulated radiotherapy with androgen deprivation therapy.
Urology. 2015 Feb;85(2):407-13.

18. Akiyoshi T, Ueno M, Ono R, Urakami S. Laparoscopic resection of sigmoid colon cancer involving the left ureter with reconstruction by ileal interposition.
Dis Colon Rectum. 2014 Oct;57(10):1241.

19. Tanaka H, Yuasa T, Fujii Y, Sakura M, Urakami S, Yamamoto S, Masuda H, Fukui I, Yonese J. First-line combination chemotherapy with cisplatin, etoposide and ifosfamide for the treatment of disseminated germ cell cancer: re-evaluation in the granulocyte colony-stimulating factor era.
Chemotherapy. 2013;59(6):441-6.

20. Urakami S. Editorial comment from Dr Urakami to impact of obesity on the predictive accuracy of prostate-specific antigen density and prostate-specific antigen in native Korean men undergoing prostate biopsy.
Int J Urol. 2014 Oct;21(10):990-1.

21. Yuasa T, Urakami S. Kidney cancer: decreased incidence of skeletal-related events in mRCC.
Nat Rev Urol. 2014 Apr;11(4):193-4.

22. Yamamoto S, Kawakami S, Yonese J, Fujii Y, Urakami S, Kitsukawa S, Masuda H, Ishikawa Y, Kozuka T, Oguchi M, Kohno A, Fukui I. Long-term oncological outcome in men with T3 prostate cancer: radical prostatectomy versus external-beam radiation therapy at a single institution.
Int J Clin Oncol. 2014 Dec;19(6):1085-91.

23. Yamamoto S, Fujii Y, Masuda H, Urakami S, Saito K, Kozuka T, Oguchi M, Fukui I, Yonese J. Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer.
Qual Life Res. 2014 Jun;23(5):1641-50.

24. Fujii Y, Yamamoto S, Yonese J, Masuda H, Urakami S, Kitsukawa S, Sakura M, Yuasa T, Kihara K, Fukui I. The processus vaginalis transection method to prevent postradical prostatectomy inguinal hernia: long-term results.
Urology. 2014 Jan;83(1):247-52.

25. Urakami S, Fujii Y, Yamamoto S, Yuasa T, Kitsukawa S, Sakura M, Yano A, Saito K, Masuda H, Yonese J, Fukui I. Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.
Urol Oncol. 2014 Jan;32(1):35.e1-7.

26. Yasuda Y, Yuasa T, Yamamoto S, Urakami S, Ito M, Sukegawa G, Kitsukawa S, Yonese J, Fukui I. Evaluation of the RENAL nephrometry scoring system in adopting nephron-sparing surgery for cT1 renal cancer.
Urol Int. 2013;90(2):179-83.

27. Yuasa T, Yamamoto S, Urakami S, Fukui I, Yonese J. Denosumab: a new option in the treatment of bone metastases from urological cancers.
Onco Targets Ther. 2012;5:221-9

28. Yasuda Y, Fujii Y, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I. Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma.
Int J Clin Oncol. 2012 Sep 11. [Epub ahead of print]

29. Yasuda Y, Saito K, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I. Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Int J Clin Oncol. 2012 Aug 11. [Epub ahead of print]

30. Saito K, Urakami S, Komai Y, Yasuda Y, Kubo Y, Kitsukawa S, Okubo Y, Yamamoto S, Yonese J, Fukui I. Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin.
BJU Int. 2012 Nov;110(10):1478-84.

31. Yamamoto S, Kawakami S, Yonese J, Fujii Y, Urakami S, Masuda H, Numao N, Ishikawa Y, Kohno A, Fukui I. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy.
Jpn J Clin Oncol. 2012 Jun;42(6):541-7.

32. Ito M, Saito K, Yasuda Y, Sukegawa G, Kubo Y, Numao N, Kitsukawa S, Urakami S, Yuasa T, Yamamoto S, Yonese J, Fukui I. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel.
Urology. 2011 Nov;78(5):1131-5.

33. Yuasa T, Tsuchiya N, Urakami S, Horikawa Y, Narita S, Inoue T, Saito M, Yamamoto S, Yonese J, Fukui I, Nakano K, Takahashi S, Hatake K, Habuchi T. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
BJU Int. 2012 May;109(9):1349-54.

34. Urakami S, Yonese J, Yamamoto S, Yuasa T, Kitsukawa S, Numao N, Kubo Y, Ito M, Sukegawa G, Yasuda Y, Ishikawa Y, Fukui I. Outcome of antegrade radical prostatectomy with intended wide resection in prostate cancer patients with a preoperative serum PSA level >100 ng/ml.
Urol Int. 2011;87(2):175-81.

35. I noue S, Shiina H, Arichi N, Mitsui Y, Hiraoka T, Wake K, Sumura M, Honda S, Yasumoto H, Urakami S, Matsubara A, Igawa M. Identification of lymphatic pathway involved in the spreading of prostate cancer by fluorescence navigation approach with intraoperatively injected indocyanine green.
Can Urol Assoc J. 2011 Aug;5(4):254-9.

36. Inoue S, Shiina H, Arichi N, Mitusi Y, Hiraoka T, Wake K, Sumura M, Honda S, Urakami S, Igawa M. Rare complication of a sigmoid colon perforation after a kidney transplant with an artificial vascular graft.
Exp Clin Transplant. 2011 Jun;9(3):207-10.

37. Yuasa T, Urakami S, Yamamoto S, Yonese J, Saito K, Takahashi S, Hatake K, Fukui I. Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis.
Clin Exp Metastasis. 2011 Apr;28(4):405-11.

38. Yuasa T, Urakami S, Yamamoto S, Yonese J, Nakano K, Kodaira M, Takahashi S, Hatake K, Inamura K, Ishikwa Y, Fukui I. Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
Urology. 2011 Apr;77(4):831-5.

39. Inoue S, Shiina H, Sumura M, Urakami S, Matsubara A, Igawa M. Impact of a novel, extended approach of perineal radical prostatectomy on surgical margins in localized prostate cancer.
BJU Int. 2010 Jul;106(1):44-8.

40. Regan MM, O'Donnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.
Ann Oncol. 2010 Feb;21(2):312-8.

41. Kawakami T, Urakami S, Hirata H, Tanaka Y, Nakajima K, Enokida H, Shiina H, Ogishima T, Tokizane T, Kawamoto K, Miura K, Ishii N, Dahiya R. Superoxide dismutase analog (Tempol: 4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl) treatment restores erectile function in diabetes-induced impotence.
Int J Impot Res. 2009 Nov-Dec;21(6):348-55.

42. Inoue S, Shiina H, Hiraoka T, Mitsui Y, Sumura M, Urakami S, Igawa M. Retrospective analysis of the distance between the neurovascular bundle and prostate cancer foci in radical prostatectomy specimens: its clinical implication in nerve-sparing surgery.
BJU Int. 2009 Oct;104(8):1085-90.

43. Inoue S, Shiina H, Hiraoka T, Wake K, Sumura M, Honda S, Urakami S, Igawa M, Usui T. Five-year longitudinal effect of radical perineal prostatectomy on health-related quality of life in Japanese men, using general and disease-specific measures.
BJU Int. 2009 Oct;104(8):1077-84.

44. Kikuno N, Kawamoto K, Hirata H, Vejdani K, Kawakami K, Fandel T, Nunes L, Urakami S, Shiina H, Igawa M, Tanagho E, Dahiya R. Nerve growth factor combined with vascular endothelial growth factor enhances regeneration of bladder acellular matrix graft in spinal cord injury-induced neurogenic rat bladder.
BJU Int. 2009 May;103(10):1424-8.

45. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Majid S, Igawa M, Dahiya R. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells.
Int J Cancer. 2008 Aug 1;123(3):552-60.

46. Urakami S, Hiraoka T, Inoue S, Wake K, Kikuno N, Sumura M, Honda S, Shiina H, Ishikawa N, and Igawa M. Long-term control or possible cure? In stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade. Int Urol Nephrol. 2008;40(2):365-8.

47. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Place RF, Pookot D, Majid S, Igawa M, Dahiya R. Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity.
Oncogene. 2007 Dec 6;26(55):7647-55.

48. Kikuno N, Urakami S, Nakamura S, Hiraoka T, Hyuga T, Arichi N, WakeK, Sumura M, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M. Phase-II Study of Docetaxel, Estramustine phosphate, and Carboplatin in Patients with Hormone-refractory Prostate Cancer.
Eur Urology. 2007 May;51(5):1252-8.

49. Urakami S, Shiina H, Enokida H, Kawamoto K, Kikuno N, Fandel T, Vejdani K, Nunes L, Igawa M, Dahiya R. Tanagho EA. Functional Immprovement in spinal cord injuty-induced neurogenic bladder by bladder augmentation using bladder acellular matrix graft in the rat.
W J Urology. 2007 Apr;25(2):207-13.

50. Kawamoto K, Okino ST, Place RF, Li LC, Enokida H, Urakami S, Hirata H, Kikuno N, Nakagawa M, Dahiya R. Epigenetic Modifications of RASSF1A Gene through chromatin remodeling in Prostate Cancer.
Clin Cancer Res. 2007 May 1;13(9):2541-8.

51. Kikuno N, Urakami S, Nakamura S, Shiina H, Igawa M. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
Int J Urol. 2007 Jan;14(1):82-4.

52. Tanaka Y, Hirata H, Chen Z, Kikuno N, Kawamoto K, Majid S, Tokizane T, Urakami S, Shiina H, Nakajima K, Rajvir D. Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer
Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):92-7.

53. Urakami S, Shiina H, Enokida H, Hirata H, Kawakami T, Kawamoto K, Tanaka Y, Kikuno N, Nakagawa M, Igawa M, Dahiya R. Wnt-antagonist family genes as biomarkers for diagnosis, staging and prognosis of renal cell carcinoma using tumor and serum DNA.
Clin Cancer Res. 2006 Dec 1;12(23):6989-97.

54. Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, Enokida H, Dahiya R. Small dsRNAs induce transcriptional activation in human cells.
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17337-42. Epub 2006 Nov 3.

55. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, Igawa M. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6116-24.

56. Okino ST, Pookot D, Li LC, Zhao H, Urakami S, Shiina H, Igawa M, Dahiya R. Epigenetic inactivation of the dioxin-responsive cytochrome P4501A1 gene in human prostate cancer.
Cancer Res. 2006 Aug 1;66(15):7420-8.

57. Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, Hirata H, Tanaka Y, Kikuno N, Nakagawa M, Igawa M, Dahiya R. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2109-16.

58. Hirata H, Hinoda Y, Matsuyama H, Tanaka Y, Okayama N, Suehiro Y, Zhao H, Urakami S, Kawamoto K, Kawakami T, Igawa M, Naito K, Dahiya R. Polymorphisms of DNA repair genes are associated with renal cell carcinoma.
Biochem Biophys Res Commun. 2006 Apr 21;342(4):1058-62. Epub 2006 Feb 17.

59. Tanaka Y, Sasaki M, Shiina H, Tokizane T, Deguchi M, Hirata H, Hinoda Y, Okayama N, Suehiro Y, Urakami S, Kawakami T, Kaneuchi M, Pookot D, Igawa M, Okuyama A, Ishii N, Dahiya R. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer.
Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):238-44.

60. Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, Tanaka Y, Li LC, Ribeiro-Filho LA, Terashima M, Kikuno N, Adachi H, Yoneda T, Kishi H, Shigeno K, Konety BR, Igawa M, Dahiya R. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
Clin Cancer Res. 2006 Jan 15;12(2):383-91.

61. Enokida H, Shiina H, Urakami S, Terashima M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Igawa M, Dahiya R. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma.
Cancer. 2006 Jan 1;106(1):79-86.

62. Yoneda T, Adachi H, Urakami S, Kishi H, Shigeno K, Shiina H, Igawa M. Health related quality of life after orthotopic neobladder construction and its comparison with normative values in the Japanese population.
J Urol. 2005 Nov;174(5):1944-7.

63. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Multigene methylation analysis for detection and staging of prostate cancer.
Clin Cancer Res. 2005 Sep 15;11(18):6582-8.

64. Tokizane T, Shiina H, Igawa M, Enokida H, Urakami S, Kawakami T, Ogishima T, Okino ST, Li LC, Tanaka Y, Nonomura N, Okuyama A, Dahiya R. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer.
Clin Cancer Res. 2005 Aug 15;11(16):5793-801.

65. Ogishima T, Shiina H, Breault JE, Terashima M, Honda S, Enokida H, Urakami S, Tokizane T, Kawakami T, Ribeiro-Filho LA, Fujime M, Kane CJ, Carroll PR, Igawa M, Dahiya R. Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer.
Oncogene. 2005 Oct 13;24(45):6765-72.

66. Youssif M, Shiina H, Urakami S, Gleason C, Nunes L, Igawa M, Enokida H, Tanagho EA, Dahiya R. Effect of vascular endothelial growth factor on regeneration of bladder acellular matrix graft: histologic and functional evaluation.
Urology. 2005 Jul;66(1):201-7.

67. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Pookot D, Li LC, Tabatabai ZL, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer.
Int J Cancer. 2005 Aug 20;116(2):174-81.

68. Shiina H, Breault JE, Basset WW, Enokida H, Urakami S, Li LC, Okino ST, Deguchi M, Kaneuchi M, Terashima M, Yoneda T, Shigeno K, Carroll PR, Igawa M, Dahiya R. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
Cancer Res. 2005 Mar 15;65(6):2130-8.

69. Urakami S, Yoshino T, Kikuno N, Imai S, Honda S, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.
Urology. 2005 Mar;65(3):543-8.

70. Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA, Terashima M, Fujime M, Igawa M, Dahiya R. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Clin Cancer Res. 2005 Feb 1;11(3):1028-36.

71. Breault JE, Shiina H, Igawa M, Ribeiro-Filho LA, Deguchi M, Enokida H, Urakami S, Terashima M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):557-64.

72. Kawakami T, Shiina H, Igawa M, Deguchi M, Nakajima K, Ogishima T, Tokizane T, Urakami S, Enokida H, Miura K, Ishii N, Kane CJ, Carroll PR, Dahiya R. Inactivation of the hMSH3 mismatch repair gene in bladder cancer.
Biochem Biophys Res Commun. 2004 Dec 17;325(3):934-42.

73. Kikuno N, Moriyama-Gonda N, Yoshino T, Yoneda T, Urakami S, Terashima M, Yoshida M, Kishi H, Shigeno K, Shiina H, Igawa M. Blockade of paclitaxel-induced thymidine phosphorylase expression can accelerate apoptosis in human prostate cancer cells.
Cancer Res. 2004 Oct 15;64(20):7526-32.

74. Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, Verma M, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
Cancer Res. 2004 Sep 1;64(17):5956-62.

75. Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis.
J Urol. 2004 May;171(5):1855-60.

76. Moriyama-Gonda N, Igawa M, Shiina H, Urakami S, Terashima M. Decreased survival of prostate cancer cells in vitro by combined treatment of heat and an antioxidant inhibitor diethyldithiocarbamate (DDC).
Exp Toxicol Pathol. 2003 Nov;55(4):251-6.

77. Honda S, Kobayashi T, Kajino K, Urakami S, Igawa M, Hino O. Ets protein Elf-1 bidirectionally suppresses transcriptional activities of the tumor suppressor Tsc2 gene and the repair-related Nth1 gene.
Mol Carcinog. 2003 Jul;37(3):122-9.

78. Adachi H, Igawa M, Shiina H, Urakami S, Shigeno K, Hino O. Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27.
J Urol. 2003 Aug;170(2 Pt 1):601-4.

79. Kikuno N, Yoshino T, Urakami S, Shigeno K, Kishi H, Hata K, Shiina H, Igawa M. The role of thymidine phosphorylase (TP) mRNA expression in angiogenesis of prostate cancer.
Anticancer Res. 2003 Mar-Apr;23(2B):1305-12.

80. Shiina H, Igawa M, Breault J, Ribeiro-Filho L, Pookot D, Urakami S, Terashima M, Deguchi M, Yamanaka M, Shirai M, Kaneuchi M, Kane CJ, Dahiya R. The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma.
Clin Cancer Res. 2003 Jun;9(6):2121-32.

81. Yoneda T, Igawa M, Shiina H, Shigeno K, Urakami S. Postoperative morbidity, functional results and quality of life of patients following orthotopic neobladder reconstruction.
Int J Urol. 2003 Mar;10(3):119-25.

82. Shigeno K, Igawa M, Shiina H, Kishi H, Urakami S. Transrectal colour Doppler ultrasonography for quantifying angiogenesis in prostate cancer.
BJU Int. 2003 Feb;91(3):223-6.

83. Urakami S, Igawa M, Kikuno N, Yoshino T, Kishi H, Shigeno K, Shiina H. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer.
J Urol. 2002 Dec;168(6):2444-50.

84. Kikuno N, Urakami S, Shigeno K, Kishi H, Shiina H, Igawa M. Traumatic rhabdomyolysis resulting from continuous compression in the exaggerated lithotomy position for radical perineal prostatectomy.
Int J Urol. 2002 Sep;9(9):521-4.

85. Urakami S, Igawa M, Shiina H, Shigeno K, Kikuno N, Yoshino T. Recurrent transitional cell carcinoma in a child with the Costello syndrome.
J Urol. 2002 Sep;168(3):1133-4.

86. Moriyama-Gonda N, Igawa M, Shiina H, Urakami S, Shigeno K, Terashima M. Modulation of heat-induced cell death in PC-3 prostate cancer cells by the antioxidant inhibitor diethyldithiocarbamate.
BJU Int. 2002 Aug;90(3):317-25.

87. Shiina H, Igawa M, Urakami S, Shigeno K, Yoneda T, Terashima M, Deguchi M, Ribeiro-Filho L, Dahiya R. Alterations of beta- and gamma-catenin in N-butyl-N-(-4-hydroxybutyl)nitrosamine-induced murine bladder cancer.
Cancer Res. 2001 Oct 1;61(19):7101-9.

88. Kikuno N, Urakami S, Shigeno K, Shiina H, Igawa M. Urachal carcinoma associated with increased carbohydrate antigen 19-9 and carcinoembryonic antigen.
J Urol. 2001 Aug;166(2):604.

89. Moriyama-Gonda N, Igawa M, Shiina H, Urakami S, Wada Y, Terashima M. Heat-induced cellular damage and tolerance in combination with adriamycin for the PC-3 prostate cancer cell line: relationships with cytotoxicity, reactive oxygen species and heat shock protein 70 expression.
Eur Urol. 2000 Aug;38(2):235-40.

90. Yagi H, Igawa M, Shiina H, Shigeno K, Yoneda T, Wada Y, Urakami S. Inverted papilloma of the urinary bladder in a girl.
Urol Int. 1999;63(4):258-60.

91. Urakami S, Igawa M, Shiina H, Shigeno K, Yoneda T, Yagi H. Congenital collateral urethral duplication in the frontal plane.
J Urol. 1999 Dec;162(6):2097-8.

92. Shiina H, Igawa M, Shigeno K, Yamasaki Y, Urakami S, Yoneda T, Wada Y, Honda S, Nagasaki M. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Oncology. 1999 Apr;56(3):239-47.

93. Satake N, Urakami S, Hirayama Y, Izumi K, Hino O. Biallelic mutations of the Tsc2 gene in chemically induced rat renal cell carcinoma.
Int J Cancer. 1998 Sep 11;77(6):895-900.

94. Wada Y, Igawa M, Shiina H, Shigeno K, Yokogi H, Urakami S, Yoneda T, Maruyama R. Comparison of chromosomal aberrations detected by fluorescence in situ hybridization with clinical parameters, DNA ploidy and Ki 67 expression in renal cell carcinoma.
Br J Cancer. 1998 Jun;77(11):2003-7.

95. Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T, Kawanishi M. Quantitative analysis of argyrophilic nucleolar organizar regions in transitional cell carcinoma of the bladder using silver staining.
Surgical Reseach Communication. 1997;19:15-25.

96. Urakami S, Tsuchiya H, Orimoto K, Kobayashi T, Igawa M, Hino O. Overexpression of members of the AP-1 transcriptional factor family from an early stage of renal carcinogenesis and inhibition of cell growth by AP-1 gene antisense oligonucleotides in the Tsc2 gene mutant (Eker) rat model.
Biochem Biophys Res Commun. 1997 Dec 8;241(1):24-30.

97. Kobayashi T, Urakami S, Cheadle JP, Aspinwall R, Harris P, Sampson JR, Hino O. Identification of a leader exon and a core promoter for the rat tuberous sclerosis 2 (Tsc2) gene and structural comparison with the human homolog.
Mamm Genome. 1997 Aug;8(8):554-8.

98. Urakami S, Tokuzen R, Tsuda H, Igawa M, Hino O. Somatic mutation of the tuberous sclerosis (Tsc2) tumor suppressor gene in chemically induced rat renal carcinoma cell.
J Urol. 1997 Jul;158(1):275-8

99. Urakami S, Igawa M, Shirakawa H, Shiina H, Kawanishi M. Quantitative analysis of NM23 protein immunoreactivity in renal cell carcinoma using an image analyzer.
J Urol. 1997 May;157(5):1928-31.

100. Kobayashi T, Urakami S, Hirayama Y, Yamamoto T, Nishizawa M, Takahara T, Kubo Y, Hino O. Intragenic Tsc2 somatic mutations as Knudson's second hit in spontaneous and chemically induced renal carcinomas in the Eker rat model.
Jpn J Cancer Res. 1997 Mar;88(3):254-61.

101. Urakami S, Igawa M, Shiina H, Ishibe T.Urethral caruncle with coexistence of intestinal heterotopia. A case report.
Int Urol Nephrol. 1997;29(3):341-4.

102. Urakami S, Igawa M, Shirakawa H, Shiina H, Ishibe T. Inverted papilloma of the urinary bladder: a case evaluated for malignant potential.
Int Urol Nephrol. 1997;29(2):181-7.

103. Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T, Kawanishi M. Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma.
Eur Urol. 1997;31(1):73-80.

104. Hino O, Mitani H, Kobayashi T, Tsuchiya H, Orimoto K, Kikuchi Y, Urakami S, Yamamoto T, Kajino K. Pathophysiological features of hereditary cancer.Gann Monograph on Cancer Reseach. 1996;44:175-187.

105. Shiina H, Igawa M, Nagami H, Yagi H, Urakami S, Yoneda T, Shirakawa H, Ishibe T, Kawanishi M. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.
Cancer. 1996 Oct 15;78(8):1762-74.

106. Shiina H, Igawa M, Urakami S, Honda S, Shirakawa H, Ishibe T. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
J Clin Pathol. 1996 May;49(5):395-9.

107. Shiina H, Igawa M, Yagi H, Urakami S, Yoneda T, Shirakawa H, Ishibe T. Immunohistochemistry of p53 protein in transitional-cell carcinoma of the bladder using an image analyzer.
Oncology. 1996 May-Jun;53(3):233-40.

108. Igawa M, Urakami S, Shirakawa H, Shiina H, Ishibe T, Kadena H, Usui T, Kawanishi M. Intravesical instillation of epirubicin: effect on tumour recurrence in patients with dysplastic epithelium after transurethral resection of superficial bladder tumour.
Br J Urol. 1996 Mar;77(3):358-62.

109. Igawa M, Urakami S, Shiina H, Ishibe T, Usui T, Chodak GW. Association of nm23 protein levels in human prostates with proliferating cell nuclear antigen expression at autopsy.

110. Igawa M, Urakami S, Shiina H, Ishibe T, Matsubara A, Kadena H, Usui T. Limitations of ureteroscopy in diagnosis of invasive upper tract urothelial cancer.
Urol Int. 1996;56(1):13-5.

111. Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T. Comparison of ureteropelvic transitional cell carcinoma with bladder transitional cell carcinoma using an image analyzer.
Urol Int. 1996;56(3):163-8.

112. Igawa M, Urakami S, Shirakawa H, Yokogi H, Shiina H, Ishibe T, Matsubara A, Usui T. Renal pelvic cancer with pulmonary metastasis:report of a case with 5-year survival following resection of metastasis.
Shimane J Med Sci. 1995-199614:33-35.

113. Igawa M, Urakami S, Shirakawa H, Shiina H, Ishibe T, Usui T. Neoadjuvant chemotherapy and badder preservation for invasive bladder cancer.
Shimane J Med Sci. 1995-199614:15-17.

114. Shiina H, Igawa M, Yagi H, Urakami S, Shirakawa H, Ishibe T. Relationship of genetic instability with immunoreactivities for p53 protein and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder.
Eur Urol. 1996;30(1):80-8.

115. Igawa M, Urakami S, Shirakawa H, Shiina H, Kishi H, Himeno Y, Ishibe T, Kadena H, Usui T. Preliminary results of concurrent methotrexate, cisplatin and radiation treatment for locally advanced urothelial cancers.
Int Urol Nephrol. 1996;28(2):189-94.

116. Shiina H, Urakami S, Shirakawa H, Igawa M, Ishibe T, Usui T. Estramustine-binding protein in carcinoma and benign hyperplasia of the human prostate.
Eur Urol. 1996;29(1):106-10.

117. Shiina H, Urakami S, Shirakawa H, Shigeno K, Himeno Y, Mizutani M, Igawa M, Ishibe T. Evaluation of the argyrophilic nucleolar organizer region, nuclear DNA content and mean nuclear area in transitional cell carcinoma of bladder using a quantitative image analyzer.
Eur Urol. 1996;29(1):99-105.

118. Urakami S, Igawa M, Shirakawa H, Shiina H, Ishibe T. Biological characteristics of inverted papilloma of the urinary bladder.
Br J Urol. 1996 Jan;77(1):55-60.

119. Igawa M, Urakami S, Shiina H, Ishibe T, Shirane T, Usui T, Chodak GW. Immunohistochemical evaluation of proliferating cell nuclear antigen, prostate-specific antigen and alpha 1-antichymotrypsin in human prostate cancer.
Br J Urol. 1996 Jan;77(1):107-12.

120. Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T. Nuclear DNA content in transitional cell carcinoma of the bladder analyzed by a quontitative image analyzer.
Diagnostic Oncology. 1995;4:214-218

121. Igawa M, Urakami S, Shirakawa H, Shiina H, Ishibe T, Kadena H, Usui T, Kawanishi M. Factors related to the outcome of M-VAC in 101 patients with advanced urothelial cancer.
Hiroshima J Med Sci. 1995 Dec;44(4):113-7.

122. Igawa M, Urakami S, Shirakawa H, Shiina H, Ishibe T, Usui T, Moriyama H. A mapping of histology and cell proliferation in human bladder cancer: an immunohistochemical study.
Hiroshima J Med Sci. 1995 Dec;44(4):93-7.

123. Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T. Immunohistochemical analysis of nm23 protein in transitional cell carcinoma of the bladder.
Br J Urol. 1995 Dec;76(6):708-13.

124. Igawa M, Urakami S, Shiina H, Ishibe T, Kadena H, Usui T. Long-term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in patients with a complete response.
Br J Urol. 1995 Sep;76(3):321-4.

125. Igawa M, Urakami S, Shiina H, Kishi H, Himeno Y, Ishibe T, Kadena H, Usui T. Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract.
Urol Int. 1995;55(2):74-7.

Copyright © 2018 冲中記念成人病研究所 All Rights Reserved.